|Table of Contents|

Construction of Tumor-specific Oncolytic Adenovirus Vector and its Primary Study on Selective Expression in Tumor Cells(PDF)

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2008年02期
Page:
92-96
Research Field:
生命科学
Publishing date:

Info

Title:
Construction of Tumor-specific Oncolytic Adenovirus Vector and its Primary Study on Selective Expression in Tumor Cells
Author(s):
Pu Yingyan; Fang Lin; Shen Quan; Sun Lijun; Hu Xiaocui; Wang Yan; Cao Xiangrong; Su Changqing
School of Life Science,Nanjing Normal University,The Jiangsu Key Laboratory of Molecular and Medical Biotechnology,Nanjing 210046,China
Keywords:
gene therapy;  onco ly tic adenov irus;  tum or;  te lom erase prom o ter
PACS:
R73-36
DOI:
-
Abstract:
To develop a nove l gene therapeu tic onco lytic adenov irus in wh ich the hTERT promo ter w as introduced and used to regulate adenov iral E1A gene. A nove l cancer- spec ific rep lication-com pe tent adenov irus nam ed AdSU w as constructed by em ploy ing the human te lom erase reverse transcr iptase ( hTERT) promo ter to dr ive the expression of adenov-i rus E1A gene and by c loning the EGFP repo rter gene into the adenov irus genom e. The non-rep licative adenov irus nam ed Ad-EGFP w as constructed as the con tro l at the sam e tim e. The se lective replication o f AdSU-EGFP in tumo r cells w as investigated by v irus pro liferative test andW estern b lo t assay. By w este rn b lot assay, E1A prote in w as pos itive in cancer ce lls (MH CC, A549) infected w ith AdSU-EGFP, but negative in norm a l ce lls ( BJ, uter ine fibroblast). Under the fluorescent m icroscope, a few norm a l cells expressed EGFP and em itted fluo rescence, and no phagocy tic p lagues appeared from 3- 10 days after infected w ith AdSU-EGFP. H ow ever, when a few cance r cells w ere infected w ith AdSU - EGFP and em itted fluo rescence afte r 3 days, the fluorescence em ission ce lls spread w ithin a large area after 7 days. Sow e can m ake a conc lusion that a nove l cancer-selective gene therapeutic onco lytic adenov irus vec to r sy stem nam ed AdSU, w hich can se lective replicate and express the rapeutic genes in cancer ce lls, was constructed. It is a prom ising system for targeted cancer gene therapy.

References:

[ 1] Shay JW, Bacchetti S. A survey o f telom erase activ ity in hum an cancer[ J]. Eur J C ancer, 1997, 33( 5) : 787-791.
[ 2] K im N W, PiatyszekM A, Prow seK R, et a.l Spec ific asso ciation o f hum an te lome rase activ ity w ith immo rtal cells and cancer[J] . Science, 1994, 266( 5193) : 2 011-2 015.
[ 3] Nemuna itis J, Gan ly I, Khuri F, et a.l Se lec tive rep lication and oncolysis in p53 mutant tumo rs w ith ONYX- 015, an E1B- 55kD g ene-de leted adenov irus, in patients w ith adv anced head and neck cancer: a phase II tria l[ J] . CancerRes, 2000,60( 22) : 6 359-6 366.
[ 4] DeW eese T L, Poe lH, Li S, et a .l A phase I tria l o f CV706, a replica tion- competent, PSA se lec tive onco ly tic adenov irus,
for the treatm ent o f lo ca lly recurrent prostate cancer fo llow ing rad ia tion therapy [ J]. C ancer Res, 2001, 61 ( 20): 7 464-7 472.
[ 5] Khur i F R, Nem una itis J, Gan ly I, et a.l A contro lled trial o f intratum ora lONYX - 015, a se lective ly- rep licating adenovirus, in com bination w ith c isp latin and 5- fluorourac il in pa tients w ith recurrent head and neck cancer[ J]. Na tM ed, 2000,6( 8): 879-885.
[ 6] H echt J R, B edford R, Abbruzzese J L, et a .l A Pahse I /II trial of intra tumo ra l endoscopic u ltrasound in jec tion o fONYX-
015 w ith intravenous gem citabine in unresectab le pancreatic carc inom a[ J]. C lin Cancer Res, 2003, 9( 2): 555-561.
[ 7] K irn D, M artuza R L, Zw iebe l J. Rep lication-se lective v irotherapy fo r cancer: bio log ica l princ ip les, r isk m anagem ent and future d irections[ J]. NatM ed, 2001, 7( 7): 781-787.
[ 8] B ischoff J R, K irn D H, W illiam sA, et a .l An adenov irus m utant tha t rep licates selective ly in p53- defic ient hum an tum or ce lls[ J]. Sc ience, 1996, 274( 5286): 373-376.
[ 9] Ro thmann T, H engsterm ann A, Wh itakerN J, et a.l Rep lication o fONYX- 015, a potential anticancer adenov irus, is independent o f p53 status in tum o r ce lls[ J] . J V iro,l 1998, 72( 12): 9 470-9 478.
[ 10] Rodr iguez R, Schuur E R, L im H R, et a.l Prostate attenua ted rep lication competent adenov irus ( ARCA) CN706: a selectivecy totox ic for prostate-spec ific antigen-positive prosta te cancer cells[ J]. Cancer Res, 1997, 57( 13): 2 559-2 563.
[ 11] K im J, Lee B, K im J S, et a .l Antitumo ra l effects o f recomb inan t adenov irus YKL - 1001, conditiona lly rep licating in alpha- fetopro te in-producing human liver cancer cells[ J]. Cancer Lett, 2002, 180( 1): 23-32.
[ 12] Kur ihara T, B rough D E, Kovesd i I, et a.l Selectivity of a replica tion- competent adenov irus for hum an b reast ca rc inoma cells expressing theMUC1 antigen[ J]. J C lin Invest, 2000, 106( 6): 763-771.
[ 13] Su C Q, Sham J, XueH B, e t a.l Potent an titum ora l e fficacy of a nove l replicative adenov irus CNHK300 ta rgeting te lom erase-
po sitive cancer ce lls[ J]. J Cancer Res C lin Onco ,l 2004, 130( 10): 591-603.
[ 14] Kaw ash ima T, Kag aw a S, Naoya K, et a .l Te lome rase- spec ific replication-selective v irothe rapy for hum an cancer[ J]. ClinCance rRes, 2004, 10( Pt1): 285-292.
[ 15] Su C Q, W ang X H, Chen J, e t a.l Antitum or activ ity of an hTERT promo ter-regu la ted tum or-se lec tive oncolytic adenov irus in hum an hepatoce llu lar carc inom a[ J]. W orld J Gastroentrto ,l 2006, 12( 47): 7 613-7 620.

Memo

Memo:
-
Last Update: 2013-05-05